{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T13:26:16Z","timestamp":1793885176751,"version":"4.8.0"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"vor","delay-in-days":20,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","valueinhealthjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jval.2026.06.029","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T23:17:25Z","timestamp":1788995845000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["An Application of Iterative Health Economic Evaluation: An Update on the Early Cost Effectiveness of Whole Genome Sequencing in Advanced Non-small Cell Lung Cancer"],"prefix":"10.1016","author":[{"given":"Andrea","family":"Fern\u00e1ndez Coves","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bram","family":"Ramaekers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martijn","family":"Simons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas F.","family":"van Schaik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Grimm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valesca P.","family":"Ret\u00e8l","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Joore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.jval.2026.06.029_bib1","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.annonc.2022.12.009","article-title":"Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Hendriks","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jval.2026.06.029_bib2","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ejca.2024.114125","article-title":"Regional differences in predictive biomarker testing rates for patients with metastatic NSCLC in the Netherlands","volume":"205","author":"de Jager","year":"2024","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jval.2026.06.029_bib3","article-title":"Developments in predictive biomarker testing and targeted therapy in advanced stage non-small cell lung cancer and their application across European countries","volume":"38","author":"de Jager","year":"2024","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.jval.2026.06.029_bib4","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.lungcan.2021.02.026","article-title":"The evolving landscape of biomarker testing for non-small cell lung cancer in Europe","volume":"154","author":"Kerr","year":"2021","journal-title":"Lung Cancer (Amsterdam, Netherlands)"},{"issue":"1","key":"10.1016\/j.jval.2026.06.029_bib5","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s12874-022-01571-3","article-title":"Developing a dynamic simulation model to support the nationwide implementation of whole genome sequencing in lung cancer","volume":"22","author":"van de Ven","year":"2022","journal-title":"BMC Med Res Methodol"},{"issue":"1","key":"10.1016\/j.jval.2026.06.029_bib6","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41436-019-0618-7","article-title":"The complete costs of genome sequencing: a microcosting study in cancer and rare diseases from a single center in the United Kingdom","volume":"22","author":"Schwarze","year":"2020","journal-title":"Genet Med"},{"issue":"1","key":"10.1016\/j.jval.2026.06.029_bib7","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1186\/s12885-021-08214-8","article-title":"Whole genome sequencing in oncology: using scenario drafting to explore future developments","volume":"21","author":"van de Ven","year":"2021","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.jval.2026.06.029_bib8","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41591-023-02697-7","article-title":"The grand challenge of moving cancer whole genome sequencing into the clinic","volume":"30","author":"Akhoundova","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.jval.2026.06.029_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2024.104441","article-title":"Factors for a broad technology assessment of comprehensive genomic profiling in advanced cancer, a systematic review","volume":"202","author":"van Schaik","year":"2024","journal-title":"Crit Rev Oncol\/Hematol"},{"issue":"12","key":"10.1016\/j.jval.2026.06.029_bib10","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1007\/s40273-021-01073-y","article-title":"Early cost effectiveness of whole genome sequencing as a clinical diagnostic test for patients with inoperable stage IIIB,C\/IV non-squamous non-small-cell lung cancer","volume":"39","author":"Simons","year":"2021","journal-title":"Pharmacoeconomics"},{"issue":"3","key":"10.1016\/j.jval.2026.06.029_bib11","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1080\/14737167.2021.1917385","article-title":"Micro-costing diagnostics in oncology: from single-gene testing to whole- genome sequencing","volume":"21","author":"Pasmans","year":"2021","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"2","key":"10.1016\/j.jval.2026.06.029_bib12","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/path.5988","article-title":"Feasibility of whole genome sequencing-based tumor diagnostics in routine pathology practice","volume":"258","author":"Samsom","year":"2022","journal-title":"J Pathol"},{"issue":"1","key":"10.1016\/j.jval.2026.06.029_bib13","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s41669-020-00220-z","article-title":"Trends in drug costs and overall survival in patients with metastatic non-small cell lung cancer in the Netherlands diagnosed from 2008 through 2014","volume":"5","author":"Cramer-van der Welle","year":"2021","journal-title":"Pharmacoecon Open"},{"issue":"1","key":"10.1016\/j.jval.2026.06.029_bib14","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1017\/S0266462322000484","article-title":"Economic evaluation of genomic\/genetic tests: a review and future directions","volume":"38","author":"Bouttell","year":"2022","journal-title":"Int J Technol Assess Health Care"},{"issue":"7","key":"10.1016\/j.jval.2026.06.029_bib15","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/j.jval.2021.11.1373","article-title":"A conceptual framework for life cycle health technology assessment","volume":"25","author":"Kirwin","year":"2022","journal-title":"Value Health"},{"issue":"1","key":"10.1016\/j.jval.2026.06.029_bib16","first-page":"42","article-title":"Exploratory, participatory and iterative assessment of value: a response to recent commentaries","volume":"10","author":"Grutters","year":"2021","journal-title":"Int J Health Policy Manag"},{"issue":"3","key":"10.1016\/j.jval.2026.06.029_bib17","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s40273-022-01229-4","article-title":"Living health technology assessment: issues, challenges and opportunities","volume":"41","author":"Thokala","year":"2023","journal-title":"Pharmacoeconomics"},{"issue":"4","key":"10.1016\/j.jval.2026.06.029_bib18","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1017\/S0266462308080604","article-title":"Integrating health economics modeling in the product development cycle of medical devices: a Bayesian approach","volume":"24","author":"Vallejo-Torres","year":"2008","journal-title":"Int J Technol Assess Health Care"},{"issue":"6","key":"10.1016\/j.jval.2026.06.029_bib19","first-page":"260","article-title":"Modeling in early stages of technology development: is an iterative approach needed? Comment on \u201cproblems and promises of health technologies: the role of early health economic modeling.\u201d","volume":"9","author":"Drummond","year":"2020","journal-title":"Int J Health Policy Manag"},{"issue":"1","key":"10.1016\/j.jval.2026.06.029_bib20","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1177\/135581969700200107","article-title":"The iterative use of economic evaluation as part of the process of health technology assessment","volume":"2","author":"Sculpher","year":"1997","journal-title":"J Health Serv Res Policy"},{"issue":"2","key":"10.1016\/j.jval.2026.06.029_bib21","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s40273-019-00855-9","article-title":"Development and validation of the TRansparent uncertainty ASsessmenT (TRUST) tool for assessing uncertainties in health economic decision models","volume":"38","author":"Grimm","year":"2020","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jval.2026.06.029_bib22","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.critrevonc.2020.103035","article-title":"Observed versus modelled lifetime overall survival of targeted therapies and immunotherapies for advanced non-small cell lung cancer patients\u2014a systematic review","volume":"153","author":"Simons","year":"2020","journal-title":"Crit Rev Oncol\/Hematol"},{"key":"10.1016\/j.jval.2026.06.029_bib23","series-title":"Zorginstituut Nederland","article-title":"Costing manual [in Dutch: Kostenhandleiding]","author":"Hakkaart-van Roijen","year":"2016"},{"key":"10.1016\/j.jval.2026.06.029_bib24","series-title":"DBC Zorgproducten Tariefapplicatie","year":"2020"},{"issue":"25","key":"10.1016\/j.jval.2026.06.029_bib29","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1056\/NEJMoa2103695","article-title":"Sotorasib for lung cancers with KRAS p.G12C Mutation","volume":"384","author":"Skoulidis","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jval.2026.06.029_bib30","series-title":"Update on micro-costing diagnostics in oncology","year":"2026"},{"key":"10.1016\/j.jval.2026.06.029_bib31","author":"van Twillert"},{"key":"10.1016\/j.jval.2026.06.029_bib32","series-title":"Kankerbehandeling transformeert\u2014moleculaire diagnostiek uit de houdgreep","author":"Gr\u00fcnberg","year":"2022"},{"key":"10.1016\/j.jval.2026.06.029_bib33","series-title":"Kijk op Moleculaire diagnostiek voor precisie oncologie. Supplement to Oncologie Up-to-Date","author":"Gr\u00fcnberg","year":"2022"},{"key":"10.1016\/j.jval.2026.06.029_bib34","series-title":"Standaard Passantenprijzen overige zorgproducten","year":"2024"},{"key":"10.1016\/j.jval.2026.06.029_bib35","series-title":"Passantentarieven MSZ Dijklander Ziekenhuis","year":"2024"},{"key":"10.1016\/j.jval.2026.06.029_bib38","series-title":"Tarieven DBC zorgproducten 2024","year":"2024"},{"key":"10.1016\/j.jval.2026.06.029_bib40","series-title":"Prijslijst 2024\u202f: Passanten","year":"2024"},{"key":"10.1016\/j.jval.2026.06.029_bib42","series-title":"Passantenprijslijst DBC & OZP 2024","year":"2024"},{"key":"10.1016\/j.jval.2026.06.029_bib43","series-title":"Passanten prijslijst DBC-zorgproducten en overige zorgproducten jaar 2024","year":"2024"},{"key":"10.1016\/j.jval.2026.06.029_bib47","series-title":"Zorginstituut Nederland","article-title":"Costing manual: methods and Reference Prices for Economic Evaluations in Healthcare","author":"Hakkaart-van Roijen","year":"2024"},{"issue":"6348","key":"10.1016\/j.jval.2026.06.029_bib48","first-page":"1","article-title":"A different animal? Identifying the features of health technology assessment for developers of medical technologies","volume":"1471","author":"Bouttell","year":"2020","journal-title":"Int J Technol Assess Health Care"},{"issue":"1","key":"10.1016\/j.jval.2026.06.029_bib49","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/s41591-023-02682-0","article-title":"Insights for precision oncology from the integration of genomic and clinical data of 13 880 tumors from the 100 000 Genomes Cancer Programme","volume":"30","author":"Sosinsky","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.jval.2026.06.029_bib50","doi-asserted-by":"crossref","first-page":"309","DOI":"10.2147\/CEOR.S191382","article-title":"The impact of increased post-progression survival on the cost-effectiveness of interventions in oncology","volume":"11","author":"Retzler","year":"2019","journal-title":"Clinicoecon Outcomes Res"},{"key":"10.1016\/j.jval.2026.06.029_bib51","article-title":"Prospective comprehensive genomic profiling of primary and metastatic prostate tumors","volume":"3","author":"Chung","year":"2019","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.jval.2026.06.029_bib52","article-title":"Cost-effectiveness of parallel versus sequential testing of genetic aberrations for Stage IV non\u2013small-cell lung cancer in the Netherlands","volume":"6","author":"Wolff","year":"2022","journal-title":"JCO Precis Oncol"},{"issue":"9","key":"10.1016\/j.jval.2026.06.029_bib53","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/j.jval.2024.04.023","article-title":"Assessing the cost-effectiveness of next-generation sequencing as a biomarker testing approach in oncology and policy implications: a literature review","volume":"27","author":"Mirza","year":"2024","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2026.06.029_bib54","first-page":"100","article-title":"Real-world cost-effectiveness of multi-gene panel sequencing to inform therapeutic decisions for advanced non-small cell lung cancer: a population-based study","volume":"40","author":"Krebs","year":"2024","journal-title":"Lancet Reg Health Am"},{"issue":"10","key":"10.1016\/j.jval.2026.06.029_bib55","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/gim.2017.247","article-title":"Are whole-exome and whole genome sequencing approaches cost-effective? A systematic review of the literature","volume":"20","author":"Schwarze","year":"2018","journal-title":"Genet Med"},{"issue":"1","key":"10.1016\/j.jval.2026.06.029_bib56","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jval.2022.07.006","article-title":"Cost-effectiveness and budget impact of future developments with whole genome sequencing for patients with lung cancer","volume":"26","author":"Simons","year":"2023","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2026.06.029_bib57","first-page":"100","article-title":"Future perspective for the application of predictive biomarker testing in advanced stage non-small cell lung cancer","volume":"38","author":"de Jager","year":"2024","journal-title":"Lancet Reg Health Eur"},{"issue":"7","key":"10.1016\/j.jval.2026.06.029_bib58","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s40273-017-0509-1","article-title":"Emerging use of early health technology assessment in medical product development: a scoping review of the literature","volume":"35","author":"Ijzerman","year":"2017","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"10.1016\/j.jval.2026.06.029_bib59","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1186\/s12885-024-13167-9","article-title":"Relevant factors for policy concerning comprehensive genomic profiling in oncology: stakeholder perspectives","volume":"24","author":"van Schaik","year":"2024","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jval.2026.06.029_bib60","doi-asserted-by":"crossref","first-page":"69","DOI":"10.12688\/wellcomeopenres.15807.2","article-title":"Making health economic models Shiny: a tutorial","volume":"5","author":"Smith","year":"2020","journal-title":"Wellcome Open Res"},{"issue":"1","key":"10.1016\/j.jval.2026.06.029_bib61","article-title":"How can robot-assisted surgery provide value for money?","volume":"3","author":"Patel","year":"2021","journal-title":"BMJ Surg Interv Health Technol"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301526026392?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301526026392?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T12:38:13Z","timestamp":1793882293000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301526026392"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":50,"alternative-id":["S1098301526026392"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2026.06.029","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An Application of Iterative Health Economic Evaluation: An Update on the Early Cost Effectiveness of Whole Genome Sequencing in Advanced Non-small Cell Lung Cancer","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2026.06.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 International Society for Pharmacoeconomics and Outcomes Research, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}